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During fetal ontogeny, T cell progenitors entering the thymus undergo a coor-
dinate pathway ofdifferentiation. Discrete steps ofintrathymic maturation can be
monitored bythe sequential appearance ofcell surface glycoproteins, ofwhich CD2
(711, sheeperythrocyte receptor) isthoughtto bethe firstT lineage-specific differen-
tiation antigen(1). It isonly afterexpression ofCD2 thatdifferentiating thymocytes
proceedtoacquireCD4 plus CD8antigens, andfinally segregate intotwo mutually
exclusive subsets of CD2+CD3'CD4+CD8" and CD2+CD3+CD4-CD8+ mature
thymocytes (1, 2). With theappearance ofthe CD3 molecularcomplex, thymocytes
first express y/b and later a/o TCR heterodimers (3-5). This prevailing view ofT
cell ontogeny predicts that CD2 is expressed on all CD3+ T cells (1). Recently, how-
ever, CD2-CD3+ T cells have been identified both in fetal human spleen and
thymus (6), and in a subset ofCD3+TCRy/b+ peripheral blood T cells from one
individual (7). In addition, CD2- stable variants have been selected from the
CD3/TCR* leukemic Jurkat line (8). Together, these recently published data sug-
gest that the expression ofa functional CD3/TCR complex is not invariably linked
to the simultaneous expression of the CD2 differentiation antigen.
In this article we show that a minor fraction of CD2- cells can be regularly
identified among CD3'TCRa//3+ peripheral blood T cells isolated from healthy
donors. In addition, we have established IL-2-dependent long-term clones with a
stable CD2-CD3+TCRa/S+ phenotype that do not express detetable levels ofCD2
mRNA. Functional studies indicated that CD2-, CD3/TCR+ T cell clones could
be induced to proliferate, produce IL-2, and display cytotoxic effector function by
mAbs directed against CD3 orTCR. These dataidentify apreviously unrecognized
minor subset of CD2- CD3/TCRa/S+ human peripheral blood T cells and dem-
onstrate that expression ofCD2 is not a prerequisite for the surface expression of
a functional CD3/TCR-a/0- molecular complex on mature human T cells.
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Materials and Methods
Enrichment ofCD2-CD3' T Cellsfrom Peripheral Blood.
￿
Ficoll-Hypaque-separated PBMC
were depleted ofplastic-adherent cells by incubation for90 min at 37°C in RPMI 1640/10%
FCS. Nonadherent cells were separated into E-rosetting ("T cells") and nonrosetting ("non-
T") cells as described (9). E- (i.e., non-T) cells were further depleted of surface Ig' B cells
by panning on sheep anti-human Ig-coated petri dishes (10). The resulting cell population
is referred to as E-sIg.
Establishment of CD2-CD3' TCell Clones.
￿
E' and E"sIg- cells were incubated for 20 min
on ice with FITC-Leu 5b mAb (anti-CD2; Becton Dickinson & Co., Mountain View, CA)
plus phycoerythrin (PE)-conjugated Leu 4 mAb (anti-CD3; Becton Dickinson&Co.). After
washing in ice-cold PBS/1% FCS, the cells were analyzed on a EPICS V cell sorter (Coulter
Electronics, Hialeah, FL) on the basis of forward angle light scatter and fluorescence inten-
sity. Single cells of CD2'CD3' and CD2-CD3' phenotype were sorted and delivered into
wells of 96-well, round-bottomed microtiter plates (Nunc, Roskilde, Denmark) with the aid
of the EPICS V autoclone device. The culture medium was RPMI 1640 (Biochrom KG,
Berlin, FRG) supplemented with 10% heat-inactivated FCS, 2 MM L-glutamine, antibiotics,
and 10 mM Hepes buffer (complete medium). The cultures were supplemented with 105 ir-
radiated MNC feeder cells, PHA (1 1~g/ml)and 50 U/ml recombinant human IL-2 (11), and
incubated at 37°C in a humidified atmosphere of 5% C02 in air. Growing clones were ex-
panded in complete medium supplemented with 50 U/ml AL-2. Established clones were re-
stimulated every 2-3 wk with PHA (0.5 p.g/ml) plus irradiated feeder cells (106 PBMC/ml
plus 105 EBVtransformed B cell line/ml).
Phenotypic Characterization ofClones.
￿
8-12 dafterfeeding, the clones were stainedin adirect
or indirect staining procedure with the followingpanel of mAbs: Leu4-PE (anti-CD3), Leu
2a-PE (anti-CD8), OKT 4-FITC (antti-CD4; Ortho Pharmaceuticals, Raritan, NJ), BMA
031 (antiTCR-a//3; reference 12), and TCRb-1 (antiTCR'r/b; T Cell Sciences, Cambridge,
MA). In addition, the following set of anti-CD2 mAbs directed against the TllI , T112, or
T113 epitope of CD2 (13) were used: Leu 5b, OKT 11, MT 1100, 6F10.3, T11/2, MT 910,
T11/3(13-15). Forindirect staining, FITC-conjugated F(ab)2 goat anti-mouse IgG (Tago Inc.,
Burlingame, CA) was used as a second-step reagent.
Northern Blot Analysis.
￿
RNA was prepared from E-rosetting T cells or established clones
by homogenization in guanidium thiocyanate followed by centrifugation through a cushion
of CsCl. TotalRNA(20,ug/lane) waselectrophoresed on 1% agarose-formaldehyde gels,trans-
ferred to nitrocellulose, and hybridized with nick-translated DNA probes. The filters were
processed as described (5) except that washingwas carried out in 0.2 x SSC with 0.1% SDS
at 37°C. The CD2 cDNA probe (16) was kindly provided by Dr. W. A. Sewell (Imperial
Cancer Research Fund, London, U.K.). The TCR/3 gene probe was a purified Bgl II/Eco
RV fragment from theTCR0 cDNA (17) and wasobtained from Dr. T. Mak(Ontario Cancer
Research Institute, Toronto, Canada).
Cell Proliferation andIL-2 Production.
￿
Cloned T cells were cultured at 5 x 104 cells per well
in round-bottomed microtiter plates (Nunc) previously coated for 12 h with 10 Wg/ml goat
anti-mouse Ig (Tago Inc.). Anti-CD3/TCR mAbs or phorbolester TPA (Sigma Chemical
Co., Deisenhofen, FRG) plus ionomycin (Calbiochem-Behring Corp., San Diego, CA) were
added to the cultures as indicated in Results. All cultures were incubated at 37°C in a hu-
midified atmosphere of 5% C02 in air. After 2 d, 75 Al of culture supernatant wasremoved
from each well for determination of IL-2 content. The remaining cell pellet was pulsed for
6 h with 1 p.Ci [3H]TdR (specific activity 5 Ci/mmol) per well, and [3H]TdR uptake was
measured in a Packardliquid scintillationcounter. IL-2 present in cell-free culture superna-
tantswasdetected in abioassay on IL-2-dependent murine CTLL cells. IL-2-induced prolifer-
ation of CTLL cells was visualized by a colorimetric method (cleavage of tetrazolium salt
MTT) as described (18). The results are expressed as the mean optical density (OD) ± SD
of triplicate cultures measured at 570 nm.
Cytotoxicity Assay.
￿
Cloned T cells were incubated at various E/T ratios with 2,000 "Cr-
labeled P815 target cells in Vshaped microtiter plates in the absence or presence of OKT3
(20 ng/ml) or PHA(1 kg/ml). After4hat 37°C, 100pl ofsupernatant was removedforcountingKABELITZ ET AL .
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in a Packard gamma-counter. Spontaneous "Cr-release was determined in wells that had
received no responder cells, and maximal "Cr-release was measured in wells that had been
vigorously resuspended . Specific lysis was calculated as follows : Percent specific lysis = 100
X [(Cpmexperimental - Cptnspontaneous)/(Cprnmaximal - CpInspontaneous)] "
Results
Presence ofCD2-CD3' TCells in Peripheral Blood.
￿
We used simultaneous two-color
cytofluorometry to study the cell surface expression ofCD2 and CD3 antigens on
subsets of macrophage-depleted PBMC obtained from normal blood donors . We
took advantage of the fact that CD2 is the receptor for sheep E (19) and separated
MNC into E' (CD2') and E - subpopulations, arguing that CD2- T cells should
not form E-rosettes . After additional removal of surface sIg' B cells from E- cells
by panning on anti-Ig-coated dishes, we analyzed CD2 andCD3 expression on E'
and E-sIg- cell fractions . As shown in a representative isometric display of two-
color flow cytometric analysis in Fig. 1 A, E' cells contained, as expected, amajor
population ofCD2'CD3' (matureT cells) and a minor population ofCD2'CD3-
cells (mostly NK cells ; reference 20) . In contrast, staining ofE- sIg- cells with anti-
CD2 plus anti-CD3 mAbs clearly revealed a distinct peak ofCD2 -CD3' cells (Fig .
1 B) . We determined in six independent experiments that CD2-CD3' accounted
for 0.1-0.8% of PBMC .
Characterization ofCD2-CD3' Long-term Clones .
￿
The above results indicated that
CD2-CD3' T cells constitute a minor fraction of normal PBMC . To characterize
these cells in more detail, we established IL-2-dependent long-term clones of
CD2-CD3' (and conventional CD2'CD3') T cells with the aid of an EPICSV cell
sorter and autoclone device . A detailed phenotypic analysis of four representative
clones is shown in Fig. 2 . Clones 2 and 3 were derived from one individual, while
clones 5 and 10 were each derived from a second and third individual, respectively.
In addition to mAbs against CD3, CD4, CD8, and TCRodg, we used a panel of
anti-CD2 mAbs directed against the three known epitopes ofCD2 (13) . As seen in
Fig. 2, clones 3, 5, and 10 did not express any of the well-characterized CD2 epi-
topes, despite the fact that they all had aCD3'TCRa/#'CD4'CD8 - phenotype
and thus were mature T cells . Control clone 2 was clearly CD2' and reacted with
all anti-CD2 mAbs tested except antiT11/3 . It is known that the T113 epitope is ex-
pressed on activated but noton restingT cells (13) . Since cloned cells were analyzed
8-10 d after feeding with IL-2-supplemented medium, it is not surprising that T113
was no longer detectable on clone 2 . The T113 epitope was, however, readily induced
on clone 2 shortly after restimulation with PHA (not shown) . In agreement with
FIGURE 1 .
￿
Two-colorcytofluorographic analysis ofCD2
andCD3 expression on peripheral blood lymphocytes
subsets. E-rosette-purified T cells (A) and E-rosette- plus
B cell-depleted (E-sIg- ) cells (B) were stained with
FITC-conjugated Leu 5b (anti-CD2) plus PE-conju-
gated Leu 4 (anti-CD3) mAbs. Log red fluorescence
(CD3) is depicted on the x-axis, log green fluorescence
(CD2) on they-axis, and relative cell numbers on the
z-axis .562
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FIGURE 2 .
￿
Phenotypic analysis ofIL-2-dependentT cell clones . IL-2-dependent long-term clones
were stained in a direct or indirect staining procedure with a panel of mAbs directed against
CD2, CD3, TCR-a/S, CD4, and CD8 surface antigens . The log fluorescence intensity is plotted
in 3 decades on the x-axis against the relative cell number on the y-axis .
thephenotypic analysis, clones 3, 5, and 10 did not form rosettes with sheep erythro-
cytes, while clone 2 did (not shown) . These results thus clearly demonstrate that
long-term clones with a stable CD2-CD3+TCRu/S+ phenotype can be established
fromhuman peripheral blood . Theclones described here have been in continuuous
culture for >6 mo.
Northern Blot Analysis ofCD2mRNA Expression .
￿
To investigate whether theCD2 -
or CD2+ phenotype corresponded to the level of CD2 mRNA, we performed
Northern blot analysis of totalRNA from 11 different clones and E-rosetted poly-
clonal T cells (Fig. 3 A). As expected from the phenotypic analysis, CD2 +CD3 +
clone 2 (lane 2) and several otherCD2 +CD3' clones (lanes 4, 8, 9, 12) expressedKABELITZ ET AL .
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FIGURE 3 .
￿
Northern blot analysis ofCD2 andTCRCO mRNA expression . Total RNA from
E-rosettingT cells (lane 1) or from IL-2-dependent long-term clones (lanes 2-12) was electro-
phoresed on 1% agarose-formaldehyde gels, transferred to nitrocellulose, and hybridized with
nick-translated DNA probes . The same filter was used for hybridization with the CD2 (A) and
CS probes (B) . Exposure times were 2 d (CD2) and 3 d (TCR CO), respectively . The approxi-
mate sizes of hybridizingRNA species are indicated. E* cells (lane 1) and clones 2, 3, 4, 12 (cor-
responding to lanes 2, 3, 4, 12) were derivedfrom donor I, clones 5and6 (lanes5and 6) from
donor II, clones 7-9 (lanes 7-9) from fetal thymus (reference 6), and clones 10 and Il (lanes
10 and 11) from donor III.
both the 1.7- and 1.3-kb CD2 transcripts (16) . In further agreement with the surface
marker analysis, CD2-CD3+ clones 3, 5, 6, 7, and 10 (lanes 3, 5, 6, 7, 10) did not
express detectable levels of either 1.7- or 1.3-kb CD2 mRNA . Although CD2-CD3+
clones 3, 5, 6, and 10 lacked CD2 transcripts, they did express full-length 1.3-kb
TCR C/3 transcripts (Fig . 3 B), thus lending further support to the notion that these
clones are mature CD3 +TCR-at/O + T cells . Also shown in Fig. 3 A is CD2 mRNA
expression in freshly isolated (polyclonal) T cells (lane 1) and in two previously charac-
terized clones (reference 6) established from fetal human thymus (lanes 7 and 8) .
The fetal clone displayed in lane 7was CD2-CD3+ , while the clone in lane 8 was
CD2 +CD3 + . Accordingly, CD2 mRNA was absent in clone 7, while clone 8 ex-
pressed both 1.7- and 1.3-kb transcripts . Furthermore, clone 7 lacked TCR CO tran-
scripts and clone 8 expressed only a truncatedTCR COmRNA (Fig. 3 B), in agree-
ment with theTCR ,y/6+ phenotype as revealed by reactivity with mAb TCR6-1
and nonreactivity withmAbBMA 031 (6) . Together, these data unequivocally dem-
onstrate that the failure to react with anti-CD2 mAbs in our series ofCD2 -CD3 +
T cell clones was due to the specific absence of CD2 gene expression .
Triggering ofCD2-CD3+ T Cell Clones via CD3/7L'R .
￿
T cell clones were cultured
in the presence ofanti-CM or antiTCR mAbs in microculture plates previously
coated with goat anti-mouse Ig, and IL-2 secretion and [3H]TdR uptake were de-
termined after 2 d . As shown in Table I, a proliferative response of CD2 - clones
3 and 7 was efficiently triggered by OKT3 (anti-CM) mAb . In addition, both clones
responded vigorously to stimulation with antiTCR mAbs ; while clone 3 (TCR
cdo+ , see Fig. 2) was activated by antiTCRtx/O mAb BMA 031 but not by anti-
TCR ,y/6 mAb TCR6-1, the TCR,y/6` (see above) fetal clone 7 was vigorously564
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TABLE I
Activation of CD2- T Cell Clones by Anti-CD3/TCR mAbs
Cloned T cells (5 x 104/well) were cultured for 48 h in wells of anti-mouse Ig-coated microtiter
plates in the absence or presence of OKT3 (20 ng/ml), TCRS-1 (100 ng/ml), BMA 031 (1
F+g/ml), TPA (1 ng/ml) plus ionomycin (250 ng/ml), or HL-2 (50 u/ml). 75 pl ofculture super-
natant was removed for determination of IL-2 content before pulsing the cultures with
[3H]TdR. Results of triplicate cultures t SD are given.
activated by mAb TCR6-1. Where tested (e.g., clone 3), CD2 - clones were also
stimulated by a combination of phorbolester TPA plus ionomycin. The proliferative
response of CD2- clones to anti-CD3/TCR stimulation was followed by secretion
ofsignificant amounts ofIL-2 as visualized by a colorimetric assay(cleavage of MTT)
on IL-2-dependent CTLL cells (Table I).
CD2 - T cells lack the "alternative" CD2-dependent activation pathway (13).
Therefore, we were interestedto investigate whether the absence of CD2 expression
would possibly alter the threshold of the amount of anti-CD3/TCR mAb required
for activation via CD3/TCR. To address this question, CD2-CD3+ and CD2+CD3+
clones were cultured in the presence of anti-CD3 or antiTCR mAbs titrated over
a wide range of concentrations. As illustrated in Fig. 4, proliferation of the CD2-
clone 3 could be efficiently stimulated by as little as 0.5 ng/ml OKT3 mAb, while
the CD2 + control clone 4 required 5 ng/ml. Comparable results (not shown) were
obtained when T cell clones were stimulated with titrated concentrations of anti-
TCR mAb BMA 031. From these results we concluded that the absence of CD2
antigen expression did not reduce the sensitivity of T cell triggering via the CD3/TCR
molecular complex.
Finally, triggering of cytotoxic effector function was tested as a third functional
parameter to analyze the impact oflack of CD2 expression on CD3/TCRmediated
T cell signaling. To this end, T cell clones were incubated at various effector/target
ratios with 51Cr-labeled Fc receptor-positive P815 target cells in the absence or pres-
ence of OKT3 (20 ng/ml) or PHA (1 kg/ml). As shown in Fig. 5, neither CD2 -
(clone 5 and 7) nor CD2 + (clone 4) T cells lysed P815 in the absence ofOKT3 mAb
Clone Phenotype Stimulation Proliferation
cpm x 10-3 t SD
IL-2 secretion
OD x 10-3 t SD
3 CD2- - 1 .4 f 0.1 3 t 1
OKT3 37.1 t 2 .1 397 t 48
BMA 031 27.3 t 0 .5 389 f 18
TCR8-1 1 .7 t 0 .2 5 t 1
TPA + iono 28.8 t 2 .0 509 t 52
HL-2 31 .9 t 0.5 ND
4 CD2' - 1 .510.1 0
OKT3 20.6 t 0.3 265 t 30
BMA 031 13.5 t 0.7 296 t 18
rIL-2 4.1 t 0.3 ND
7 CD2- - 2 .8 t 0.1 0
OKT3 48.2 t 5.7 139 t 32
TCR6-1 49.6 t 3.4 422 t 32
rIL-2 28.1 t 2.4 NDN
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FIGURE 4. Proliferative re-
sponse of CD2 - clone 3 and
CD2* clone 4 to OKT3 mAb .
Cloned T cells (5 x 104/well)
were cultured in triplicate in
anti-mouse Ig-coated micro-
titer plates in thepresenceofthe
indicated amounts of OKT3 .
[3H]TdR uptake was deter-
mined after 48 h .
FIGURE 5 .
￿
Cytotoxic activity ofCD2 - and
CD2* T cell clones. Cytotoxic effector ac-
tivity of CD2 - clones 5 and 7 and CD2*
clone 4 was measured at the indicated E/T
ratios against P815 target cells in the absence
(O) or presence of 1 FIg/ml PHA (") or 20
ng/ml OKT3 (A) .
orPHA. On the other hand, cytotoxic effector activity could be triggered by anti-
CD3 mAb OKT3 (and by PHA) independent of whetherT cell clones did (clone
4) or did not (clone 5 and 7) express CD2.
Discussion
Our results demonstrate that a small subset ofCD3/TCR' peripheral blood T
cells do not express the CD2 antigen . Although CD2- cells have been previously
identified amongCD3/TCRy/S' T cells from one particular individual (7), as well
as amongCD3' T cells in fetal spleen and thymus (6), the present study is the first
to identify CD2 - cells within nontransformed CD3/TCRa//3' human T cells.
CD2-CD3' T cells were enriched by depletion of macrophages, E-rosettingT cells
and B cells, and accounted for 0.1-0.8% of all PBMC . IL-2-dependent long-term
clones ofCD2-CD3'T cells did not react with apanel of anti-CD2 mAbs directed
against the three known epitopes ofCD2 and failed to express detectable levels of
CD2mRNA ; only one of six cell surface CD2 - clones (clone 11, Fig . 3 A) showed
a faint band of 1.7-kb CD2mRNA . With respect to its maturational stage, this clone
appears to correspond to previously described CD2- mutants of the CD3' leukemic566
￿
INTERLEUKIN 2-DEPENDENT CD2-/CD3' T CELL CLONES
Jurkat line (8). As reported by Moingeon et al. (8), cell surface CD2-Jurkat vari-
ants expressed strongly reduced yet detectable levels ofeither 1.7- or 1.3-kb CD2
mRNA. It should be stressed that the CD2- Jurkat mutants described by Moin-
geon et al. (8) were derived by mutagenesis and immunoselection from CD2+ pa-
rental cells. In contrast, our present series of CD2-CD3+ clones was not derived
by mutagenesis or any other selection procedure except initial cell sorting. The
CD2- clones established here thus represent a minorsubset ofnormal PBMC. Five
ofsix cell surface CD2-CD3' T cell clones completely lacked detectable CD2 tran-
scripts.
Awidely accepted model ofTcell ontogeny proposesthatCD2 is oneoftheearliest
ifnot the first T cell-specific cell surface glycoprotein(1). Recent evidence indicates,
however, that CD3 mRNAexpression precedesCD2 mRNAexpression during fetal
murine development (21). In addition, a major population ofCD4-CD8- "double-
negative" sheep peripheral blood T cells is CD2- (22). Taken together with the iden-
tification ofCD2-CD3+ T cells in fetal human tissue (6) and adult peripheral blood
(this article), the hypothesis that CD2 is necessarily expressed on all CD3/TCR+
T cells may not be of general validity.
Human T cells can be activated through two major pathways: one of these in-
volves antigen recognition via Tcell receptor, whereas the otheris antigen indepen-
dent. Antigen-specific T cell activation can be mimicked by mAbs directed against
the CD3/TCR molecular complex (23), while the antigen-independent pathway is
initiated by a combination of mAbs directed at two distinct epitopes of the CD2
antigen (13, 24). From previous studies there is strong evidence, however, for an
interdependence ofboth pathways. Thus, it has been foundthat activation ofT cells
via CD2 requires the simultaneous expression ofa functional CD3/TCR complex
(25-27). In addition, activation of T cells via CD2 can be modulated by anti-CD3
mAbs (28) and, vice versa, TCRdependent, antigen-specific T cell stimulation is
influenced byanti-CD2 mAbs (29, 30). It has been less clear, however, whetheracti-
vation ofT cells via CD3/TCR is absolutely dependent on the simultaneous coex-
pression ofCD2. Recently, a CD2-, CD3/TCRy/S+ cell population has been de-
scribed inoneparticular individual; thesecells showed anormal response tostimulation
with anti-CD3 and antiTCR-y mAbs (7). Similarly, cell surface CD2- variants of
the CD3/TCR+ leukemic Jurkat T cell line were found to respond to anti-CD3 or
antiTCR signaling by Cat+ influx and IL-2 production (8). These studies have not
established, however, whether normal (i.e., nontransformed) T cells with a conven-
tional TCRa//3 molecule can be activated via CD3/TCR in the absence of CD2
expression. Our present results now clearly demonstrate that CD2-, CD3+ Tcell
clones canbeinduced toproliferate, secrete IL-2, anddisplaycytotoxic elfectorfunction
by mAbs directed against CD3 or TCR. Thus, at least with respect to the three
functional parameters tested, signaling via CD3/TCR appeared to be fully main-
tained in CD2- Tcell clones . This was true for both a//3 and y/S TCR-expressing
T cells; while anti-CD3 mAb OKT3 triggered both types ofclones, mAb BMA 031
activated TCRy/(3+ clones and mAb TCRS1 activated TCRy/S+ clones, respec-
tively.
In conclusion, our studies have identified and characterized a novel subset of
CD2-CD3/TCRa//3' human peripheral blood T cells. In addition, we have shown
thatTcell signaling via TCRy/S or-WO can proceed in the absence ofCD2 antigenexpression. Further studies will be required, however, to address the question how
the lack of CD2 expression affects the antigen-specific activation of cloned T cells.
Summary
It is generally believed that CD2 (Tll, sheep erythrocyte receptor) is expressed
on all human T cells. In the present study we have identified and characterized a
minor subset of CD2 - CD3/TCRa/0+ T cells in the peripheral blood of healthy
individuals. CD2 -CD3 + T cells were enriched in PBMC depleted of plastic-
adherent macrophages, E-rosetting (i.e., CD2+) T cells and surface Ig' B cells.
CD2 -CD3 + T cells accounted for 0.1-0.8% of PBMC in six individuals. IL-2-
dependent long-term clones of CD2 -CD3+ T cells neither reacted with a panel of
anti-CD2 mAbs nor expressed detectable levels of CD2 mRNA by Northern blot
analysis. These clones, however, expressed a full-length TCR Cs mRNA and reacted
with mAbs against TCRa/o, CD3, and CD4, and thus were mature T cells.
CD2 -CD3/TCR + T cell clones could be triggered into proliferation, IL-2 produc-
tion, and cytotoxic effector activity by anti-CD3 and antiTCR mAbs. We conclude
that (a) a minor subset of CD2 - , CD3/TCRa/S+ T cells is present in normal pe-
ripheral blood; and (b) expression of CD2 at the level of protein and/or mRNA is
not required for T cell signaling via the CD3/TCR molecular complex.
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